Literature DB >> 25998098

Genes Encoding Vascular Endothelial Growth Factor A (VEGF-A) and VEGF Receptor 2 (VEGFR-2) and Risk for Bronchopulmonary Dysplasia.

Mari Mahlman1, Johanna M Huusko, Minna K Karjalainen, Tuula Kaukola, Riitta Marttila, Marja Ojaniemi, Ritva Haataja, Pascal M Lavoie, Mika Rämet, Mikko Hallman.   

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) is one of the main consequences of prematurity, with notably high heritability. Vascular endothelial growth factor A (VEGF-A) and its main receptor, vascular endothelial growth factor receptor 2 (VEGFR-2), have been implicated in the pathogenesis of BPD.
OBJECTIVE: To study whether common polymorphisms of the genes encoding VEGF-A and VEGFR-2 are associated with BPD.
METHODS: In this association study, six tagging single nucleotide polymorphism (tSNPs) for VEGFA and 25 tSNPs for VEGFR2 were genotyped in a prospectively collected, genetically homogeneous discovery population of 160 infants (44 infants with grade 2-3 BPD) born before 30 completed gestational weeks. The replication population of 328 infants included 120 cases of BPD.
RESULTS: VEGFR2 SNP rs4576072 was associated with BPD grade 2-3 with a minor allele frequency in 23.9% of the cases compared to 9.1% in controls (p = 0.0005, odds ratio 3.15, 95% CI: 1.62-6.12) in the discovery population. This association was not observed in the more heterogeneous replication population.
CONCLUSIONS: In line with the results of recent large-scale genetic studies, our findings indicate that common polymorphisms of the genes encoding VEGF-A and VEGFR-2 are not consistently associated with BPD. This finding does not rule out the involvement of VEGFA and VEGFR2 in BPD pathogenesis since, in addition to common variations within the gene region, other mechanisms also play important roles in the regulation of gene function.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998098     DOI: 10.1159/000381279

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  4 in total

1.  Aerosolized deferoxamine administration in mouse model of bronchopulmonary dysplasia improve pulmonary development.

Authors:  Yanru Chen; Sha Gao; Yufei Yan; Jihong Qian; Hao Chen
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

Review 2.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

Review 3.  Heart‑lung crosstalk in pulmonary arterial hypertension following myocardial infarction (Review).

Authors:  Wenfeng Ye; Haixu Guo; Jinrong Xu; Shuyun Cai; Yuan He; Xiaorong Shui; Shian Huang; Hui Luo; Wei Lei
Journal:  Int J Mol Med       Date:  2020-06-18       Impact factor: 4.101

4.  Correlation of Retinopathy of Prematurity with Bronchopulmonary Dysplasia.

Authors:  Wojciech Podraza; Beata Michalczuk; Karolina Jezierska; Hanna Domek; Agnieszka Kordek; Beata Łoniewska; Monika Modrzejewska; Joanna Kot
Journal:  Open Med (Wars)       Date:  2018-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.